Literature DB >> 32329825

MiR-654-5p regulated cell progression and tumor growth through targeting SIRT6 in osteosarcoma.

X-Z Xu1, H Song, Y Zhao, L Zhang.   

Abstract

OBJECTIVE: MiRNAs are important regulators in cell progression, tumor formation, and development. The poor prognosis and high incidence of osteosarcoma are difficult to treat. Therefore, studying the mechanism of OS progression is conducive to the diagnosis and treatment of OS. However, the role of miRNA in OS progression has not been fully explored.
MATERIALS AND METHODS: The expression of miR-654-5p and SIRT6 was detected using qRT-PCR. Western blot was applied to measure the protein expression of SIRT6. Transfected cells proliferation was measured using MTT assay. Transwell was performed to assess cell migrated and invasive capacity. Animals experiment was used to verify the regulatory mechanism of miR-654-5p in OS.
RESULTS: In this study, we found that miR-654-3p was downregulated while SIRT6 expression was upregulated in OS tissues and cells. Meanwhile, the overexpression of miR-654-5p suppressed cell proliferation, invasion, and migration in OS cells. Otherwise, Luciferase reporter assay determined that SIRT6 was a target gene of miR-654-5p. Notably, the promotion effect of anti-miR-654-5p on cell proliferation, migration, and invasion was reversed by inhibition of SIRT6 in OS. Moreover, the promotion of miR-654-5p inhibited OS tumor growth in vivo.
CONCLUSIONS: MiR-654-5p regulated cell progression and tumor growth by targeting SIRT6 in OS, providing a new therapeutic target for OS.

Entities:  

Year:  2020        PMID: 32329825     DOI: 10.26355/eurrev_202004_20811

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

Review 1.  Emerging roles of SIRT6 in human diseases and its modulators.

Authors:  Gang Liu; Haiying Chen; Hua Liu; Wenbo Zhang; Jia Zhou
Journal:  Med Res Rev       Date:  2020-12-16       Impact factor: 12.944

2.  LINC02532 Contributes to Radiosensitivity in Clear Cell Renal Cell Carcinoma through the miR-654-5p/YY1 Axis.

Authors:  Xiaoguang Zhou; Bowen Zeng; Yansheng Li; Haozhou Wang; Xiaodong Zhang
Journal:  Molecules       Date:  2021-11-22       Impact factor: 4.411

3.  miR-654-5p Contributes to the Activation and Proliferation of Hepatic Stellate Cells by Targeting RXRα.

Authors:  Heming Ma; Xiaomei Wang; Xu Liu; Chang Wang; Xiuzhu Gao; Junqi Niu
Journal:  Front Cell Dev Biol       Date:  2022-04-06

4.  Comprehensive Analysis of hsa-miR-654-5p's Tumor-Suppressing Functions.

Authors:  Chuanyang Liu; Lu Min; Jingyu Kuang; Chushu Zhu; Xinyuan Qiu; Xiaomin Wu; Tianyi Zhang; Sisi Xie; Lingyun Zhu
Journal:  Int J Mol Sci       Date:  2022-06-08       Impact factor: 6.208

5.  Zinc finger Asp-His-His-Cys palmitoyl -acyltransferase 19 accelerates tumor progression through wnt/β-catenin pathway and is upregulated by miR-940 in osteosarcoma.

Authors:  Shuhong Liang; Xiaojian Zhang; Jun Li
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

6.  Interference with circRNA DOCK1 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by regulating the miR-654-5p/SMAD2 axis.

Authors:  Yujuan Lu; Jingzhi Zhang; Yanhui Wu
Journal:  Mol Med Rep       Date:  2021-06-29       Impact factor: 2.952

7.  Long non-coding RNA Lnc-408 promotes invasion and metastasis of breast cancer cell by regulating LIMK1.

Authors:  Yina Qiao; Ting Jin; Shengdong Guan; Shaojie Cheng; Siyang Wen; Huan Zeng; Maojia Zhao; Liping Yang; Xueying Wan; Yuxiang Qiu; Qiao Li; Manran Liu; Yixuan Hou
Journal:  Oncogene       Date:  2021-06-02       Impact factor: 9.867

8.  Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma.

Authors:  Zhongkai Zhang; Sang Hoon Ha; Young Jae Moon; Usama Khamis Hussein; Yiping Song; Kyoung Min Kim; See-Hyoung Park; Ho Sung Park; Byung-Hyun Park; Ae-Ri Ahn; Sang-A Lee; Su Jin Ahn; Jung Ryul Kim; Kyu Yun Jang
Journal:  J Exp Clin Cancer Res       Date:  2020-11-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.